Investor Centre
Rewriting the future of livestock
Established in 2025, AgriCureX is an emerging leader in Australian livestock biotechnology, developing the next generation of bacteriophage therapeutics.
Our ambition is to deliver targeted, science-driven solutions that reduce antibiotic reliance and improve herd performance across the agricultural sector.
FY25 saw strong advancement in product development and early industry engagement, positioning the company for commercial scale.
AgriCureX is focused on high-growth livestock markets facing rising disease and AMR pressures, supporting our vision to become a leading provider of advanced veterinary biotechnologies at scale.
The Market Opportunity
Feedlot beef production is a cornerstone of global protein supply
Annual Production Volumes:
Australia: > 1.6M head finished in feedlots
USA: ~13M head
Key Growth markets: EU, China and Colombia are expanding feedlot operations and demand for high-quality beef.
Revenues:
AUS - $5.4B 2022 – Avg Profit 12.7%
USA - $51.9 B 2022
Global beef production is increasing: 57.6 M Ton in 2021 to 76 M Ton in 2023.
| Segment | Value | Notes |
|---|---|---|
| Australia Feedlot Market | $3.7B | ~2.3M cattle on feed |
| Global BRD Therapeutics | $1.2B+ | USA, Brazil, Canada, EU |
| AMR-aligned Biotech | $10B+ | Growing investor ingest in phage platforms |
Approx 46%
of Australian cattle experience confinement as part of their lives in feedlots
Over 80%
of the beef sold domestically is sourced from animals that were finished in feedlots.
Insights and News
Rewrite the future of livestock health
Join us in rewriting the future of livestock health and express your interest for future investment opportunities.